WorldHeart RELIANT trial
This article was originally published in The Gray Sheet
Executive Summary
Oakland, Calif.-based company reported Feb. 21 that 20 clinical centers and 29 patients have enrolled in its RELIANT destination therapy trial, which pits the Novacor pulsatile LVAD against Thoratec's HeartMate. WorldHeart anticipates that the additional centers will accelerate patient enrollment for the 390-patient trial. Thoratec's device is the only LVAD approved as a destination therapy for in the U.S. (1"The Gray Sheet" March 28, 2005, p. 17)...
You may also be interested in...
Arrow Contemplates Fate Of LVAD Business; WorldHeart, Thoratec Start Trials
Arrow International's board of directors will assess the future commercial potential of its left-ventricular assist devices at a meeting April 6-7
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.